• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma
【2h】

Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma

机译：布地奈德/福莫特罗治疗老年支气管哮喘的长期安全性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The long-term safety of budesonide/formoterol (BUD/FM) inhalation has not been fully evaluated, particularly in elderly patients with bronchial asthma. To evaluate the 12-month safety of BUD/FM inhalation for elderly asthmatic patients, the changes in serum potassium levels and pulse rate were examined. A retrospective chart review was conducted of consecutive patients who were treated with BUD/FM inhalation (two inhalations of 160/4.5 mg, twice daily; Symbicort Turbuhaler, AstraZeneca) at a hospital between February 2010 and January 2012. A total of 350 patients were treated with BUD/FM inhalation during the study period and were followed up over 12 months. The mean age of the patients was 60 years, and 19.4% and 21.4% of the patients were aged 65–74 years and ≥75 years, respectively. One hundred and fourteen (32.6%) of the 350 patients continued the inhalation therapy for >12 months. Compared with the pretreatment data, reductions in serum potassium levels at 1, 6 and 12 months were not observed, even in the patients aged 65–74 and ≥75 years. There was also no increase in the pulse rate at 1, 6 and 12 months, even in the patients aged 65–74 and ≥75 years. The usual dosage of BUD/FM showed no adverse effects on the serum potassium levels and pulse rate in the adults, including the elderly with persistent asthma.
机译：尚未完全评估布地奈德/福莫特罗（BUD / FM）吸入的长期安全性，尤其是在老年支气管哮喘患者中。为了评估老年哮喘患者BUD / FM吸入的12个月安全性，检查了血清钾水平和脉搏率的变化。回顾性图表回顾了2010年2月至2012年1月间在医院接受BUD / FM吸入治疗的连续患者（两次吸入160 / 4.5 mg，每天两次； Symbicort Turbuhaler，阿斯利康）。总共350例患者在研究期间接受BUD / FM吸入治疗，并随访12个月。患者的平均年龄为60岁，分别为65岁至74岁和≥75岁的患者分别占19.4％和21.4％。 350名患者中的一百一十四名（32.6％）继续接受吸入疗法治疗> 12个月。与预处理数据相比，即使在65-74岁和≥75岁的患者中，在1、6和12个月时血清钾水平也没有降低。即使在65-74岁和≥75岁的患者中，在1、6和12个月时脉搏率也没有增加。 BUD / FM的常规剂量对成人（包括患有持续性哮喘的老年人）的血钾水平和脉搏率无不良影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号